2023 World Conference on Lung Cancer (Posters)-EP12.01. Educational Impact of A Clinical Advances Curriculum On EGFR Exon 20 Insertion Mutated NSCLC And EGFR TKI-Resistant NSCLC

EP12.01. Educational Impact of A Clinical Advances Curriculum On EGFR Exon 20 Insertion Mutated NSCLC And EGFR TKI-Resistant NSCLC - PDF(Slides)

Back to course

Pdf Summary

A clinical advances curriculum was developed in 2021 to address the knowledge gaps that oncologists have regarding the management of EGFR exon 20 insertion mutated non-small cell lung cancer (NSCLC) and EGFR TKI-resistant NSCLC. The objective of this study was to assess the impact of this educational curriculum on the knowledge, competence, and confidence of oncologists. A series of six online CME activities were launched as part of the curriculum, covering various educational gaps in the management of these types of lung cancer. Data was collected from January 14, 2021, to February 23, 2022, and the impact was assessed using pre- and post-education knowledge, competence, and confidence questions.<br /><br />The results showed that the activities in the curriculum led to an increase in the knowledge, competence, and confidence of oncologists across five out of the seven themes assessed. However, it was noted that this field is rapidly developing, and further education will be needed to keep oncologists updated on the clinical implications of the novel data and to help them incorporate best practices in their clinics. A total of 2,439 oncologists participated in the activities, out of a total of 4,330 healthcare professionals who took part in the curriculum. The participants reported high levels of satisfaction with the program and agreed that the content learned would impact their practice. They also agreed that the program supported the achievement of the learning objectives and was presented effectively without commercial bias.<br /><br />The activities in the curriculum were supported by an independent educational grant from Janssen Oncology. For more information, readers can contact Nabil Dorkhom, MD, Director of Clinical Strategy at Medscape. It is important to note that N. Dorkhom has no conflicts of interest to declare. Overall, the study suggests that the clinical advances curriculum had a positive impact on the knowledge, competence, and confidence of oncologists in managing EGFR exon 20 insertion mutated NSCLC and EGFR TKI-resistant NSCLC, but ongoing education will be necessary to keep up with advancements in this rapidly evolving field.

Asset Subtitle

Nabil Dorkhom

Meta Tag

Speaker Nabil Dorkhom

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

clinical advances curriculum

oncologists

EGFR exon 20 insertion mutated NSCLC

EGFR TKI-resistant NSCLC

knowledge gaps

competence

confidence

online CME activities

education

clinical implications